Preliminary results from a phase II study of lenalidomide monotherapy in Relapsed/Refractory aggressive non-Hodgkin's lymphoma.

被引：0
|
作者：
Wiemik, Peter H.
Lossos, Izidore
Tuscano, Joseph
Justice, Glen
Vose, Julie M.
Pietronigro, Dennis
Takeshita, Kenichi
Ervin-Haynes, Annette
Zeldis, Jerome B.
Habermann, Thomas M.
机构：
[1] Coll Med, Our Lady Canc Ctr, Bronx, NY 33152 USA
[2] Univ Miami, Sylvester Canc Ctr, Miami, FL 95817 USA
[3] Univ Calif Davis, Ctr Canc, Sacramento, CA USA
[4] Oncol Med Grp, Fountain Valley, CA 68182 USA
[5] Univ Nebraska, Omaha, NE USA
[6] Celgene Corp, Summit, NJ USA
[7] Mayo Clin, Rochester, MN USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
531
引用
收藏
页码：160A / 161A
页数：2
相关论文
共 50 条
  • [21] Encouraging Activity of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma: Results From a Phase II Study (BO20999)
    Morschhauser, Franck
    Cartron, Guillaume
    Thieblemont, Catherine
    Solal-Celigny, Philippe
    Haioun, Corinne
    Bouabdallah, Reda
    Lamy, Thierry
    Milpied, Noel
    Le Gouill, Steven
    Feugier, Pierre
    Wenger, Michael K.
    Wassner-Fritsch, Elisabeth
    Asikanius, Elina
    Salles, Gilles Andre
    BLOOD, 2011, 118 (21) : 1562 - 1563
  • [22] Phase II study of Paclitaxel plus Topotecan with G-CSF support for the treatment of relapsed and refractory aggressive non-Hodgkin's lymphoma.
    Younes, A
    Okpara, N
    Romaguera, JE
    Hagemeister, FB
    McLaughlin, P
    Rahman, D
    Cabanillas, F
    BLOOD, 1999, 94 (10) : 270B - 270B
  • [23] RESULTS FROM A PHASE II STUDY (BO20999) OF RO5072759 (GA101) MONOTHERAPY IN RELAPSED/REFRACTORY AGGRESSIVE NON-HODGKIN'S LYMPHOMA
    Cartron, G.
    Thieblemont, C.
    Solal-Celigny, P.
    Morschhauser, F.
    Haioun, C.
    Bouabdallah, R.
    Wenger, M.
    Salles, G.
    ANNALS OF ONCOLOGY, 2011, 22 : 131 - 132
  • [24] Phase II study of paclitaxel plus topotecan with G-CSF support for the treatment of relapsed and refractory aggressive non-Hodgkin's lymphoma.
    Younes, A
    Rahman, D
    Hagemeister, F
    Romaguera, J
    McLaughlin, P
    Cabanillas, F
    BLOOD, 1998, 92 (10) : 621A - 621A
  • [25] A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma
    Hosein, Peter J.
    Craig, Michael D.
    Tallman, Martin S.
    Boccia, Ralph V.
    Hamilton, Brian L.
    Lewis, Jonathan J.
    Lossos, Izidore S.
    AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (01) : 111 - 114
  • [26] RESULTS FROM A PHASE II STUDY INVESTIGATING THE EFFICACY AND SAFETY OF LENALIDOMIDE ORAL MONOTHERAPY IN RELAPSED OR REFRACTORY INDOLENT NOW HODGKIN'S LYMPHOMA
    Peter, H. W.
    Vose, J. M.
    Moore, T. D.
    Reeder, C. B.
    Cole, C. E.
    Justice, G.
    Kaplan, H. P.
    Voralia, M.
    Pietronigro, D.
    Takeshita, K.
    Ervin-Haynes, A.
    Zeldis, J. B.
    Witzig, T. E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 107 - 107
  • [27] Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
    Witzig, Thomas E.
    Wiernik, Peter H.
    Moore, Timothy
    Reeder, Craig
    Cole, Craig
    Justice, Glen
    Kaplan, Henry
    Voralia, Michael
    Pietronigro, Dennis
    Takeshita, Kenichi
    Ervin-Haynes, Annette
    Zeldis, Jerome B.
    Vose, Julie M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (32) : 5404 - 5409
  • [28] Phase I/II Trial of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
    Kallam, Avyakta
    Meza, Jane
    Bierman, Philip
    Lunning, Matthew A.
    Bociek, R. Gregory
    Armitage, James Olen
    Vose, Julie M.
    BLOOD, 2017, 130
  • [29] NICE guidance on pixantrone monotherapy for multiply relapsed or refractory aggressive non-Hodgkin lymphoma
    Landells, Linda J.
    Prescott, Carl
    Hay, Nicola
    Sutcliffe, Frances
    Stevens, Andrew
    LANCET ONCOLOGY, 2014, 15 (04): : 381 - 382
  • [30] Efficacy of lenalidomide oral monotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma: Final results of NHL-001
    Witzig, T. E.
    Wiernik, P. H.
    Moore, T.
    Reeder, C.
    Cole, C.
    Justice, G.
    Kaplan, H.
    Voralia, M.
    Pietronigro, D.
    Vose, J. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345